Clene (CLNN) Competitors $6.11 -0.24 (-3.78%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CLNN vs. ABOS, CRBU, ADAP, LFCR, CRBP, IMMP, MDWD, VTYX, CNTX, and LFVNShould you be buying Clene stock or one of its competitors? The main competitors of Clene include Acumen Pharmaceuticals (ABOS), Caribou Biosciences (CRBU), Adaptimmune Therapeutics (ADAP), Lifecore Biomedical (LFCR), Corbus Pharmaceuticals (CRBP), Immutep (IMMP), MediWound (MDWD), Ventyx Biosciences (VTYX), Context Therapeutics (CNTX), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical products" industry. Clene vs. Acumen Pharmaceuticals Caribou Biosciences Adaptimmune Therapeutics Lifecore Biomedical Corbus Pharmaceuticals Immutep MediWound Ventyx Biosciences Context Therapeutics LifeVantage Clene (NASDAQ:CLNN) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Is CLNN or ABOS more profitable? Acumen Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -6,890.50%. Acumen Pharmaceuticals' return on equity of -24.63% beat Clene's return on equity.Company Net Margins Return on Equity Return on Assets Clene-6,890.50% -315.97% -61.47% Acumen Pharmaceuticals N/A -24.63%-21.87% Does the MarketBeat Community favor CLNN or ABOS? Clene received 43 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. Likewise, 77.91% of users gave Clene an outperform vote while only 70.59% of users gave Acumen Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCleneOutperform Votes6777.91% Underperform Votes1922.09% Acumen PharmaceuticalsOutperform Votes2470.59% Underperform Votes1029.41% Which has better valuation & earnings, CLNN or ABOS? Clene has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClene$650K64.48-$49.50M-$4.46-1.37Acumen PharmaceuticalsN/AN/A-$52.37M-$1.12-2.54 Do analysts rate CLNN or ABOS? Clene currently has a consensus price target of $72.33, suggesting a potential upside of 1,083.85%. Acumen Pharmaceuticals has a consensus price target of $9.00, suggesting a potential upside of 216.34%. Given Clene's higher possible upside, analysts plainly believe Clene is more favorable than Acumen Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media prefer CLNN or ABOS? In the previous week, Acumen Pharmaceuticals had 4 more articles in the media than Clene. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 0 mentions for Clene. Acumen Pharmaceuticals' average media sentiment score of 1.21 beat Clene's score of -0.27 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Clene Neutral Acumen Pharmaceuticals Positive Which has more volatility & risk, CLNN or ABOS? Clene has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Do insiders and institutionals believe in CLNN or ABOS? 23.3% of Clene shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 25.1% of Clene shares are held by company insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryClene beats Acumen Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Ad Porter & CompanyTrue paradigm shiftI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLNN vs. The Competition Export to ExcelMetricClenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.54M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-1.379.93114.8115.14Price / Sales64.48396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book2.925.324.665.02Net Income-$49.50M$153.56M$119.06M$225.46M7 Day Performance14.21%0.13%0.80%0.37%1 Month Performance24.95%15.23%5.65%3.57%1 Year Performance-21.22%41.14%36.75%29.43% Clene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLNNClene3.6525 of 5 stars$6.11-3.8%$72.33+1,083.9%-19.1%$43.54M$650,000.00-1.37100Upcoming EarningsABOSAcumen Pharmaceuticals3.5984 of 5 stars$2.91+0.3%$9.00+209.8%+49.7%$174.53MN/A-2.5951News CoverageGap UpCRBUCaribou Biosciences2.1193 of 5 stars$1.93+2.7%$11.25+482.9%-38.3%$174.31M$33.11M-1.39100Upcoming EarningsADAPAdaptimmune Therapeutics2.9169 of 5 stars$0.70-4.1%$3.38+380.2%+48.1%$173.89M$141.46M-2.01449Short Interest ↓News CoverageLFCRLifecore Biomedical3.0405 of 5 stars$5.73+2.0%$8.00+39.6%-16.4%$173.75M$128.44M71.63690Positive NewsCRBPCorbus Pharmaceuticals4.4642 of 5 stars$16.20-0.9%$65.86+306.5%+235.0%$173.13M$880,000.00-2.7940Upcoming EarningsShort Interest ↑IMMPImmutep0.8718 of 5 stars$1.94+1.0%$8.00+312.4%-2.7%$170.58M$5.14M0.002,021MDWDMediWound1.4641 of 5 stars$18.20+3.6%$29.00+59.3%+142.3%$168.97M$20.14M-8.4380VTYXVentyx Biosciences2.7863 of 5 stars$2.39+3.5%$8.29+246.7%-85.1%$168.90MN/A-0.8673Positive NewsCNTXContext Therapeutics3.0516 of 5 stars$2.24-2.6%$6.25+179.0%+104.5%$168.00MN/A-2.117Short Interest ↓News CoverageLFVNLifeVantage3.2054 of 5 stars$12.98-3.8%N/A+72.0%$164.86M$200.16M56.44260Earnings ReportDividend AnnouncementShort Interest ↑News CoverageHigh Trading Volume Related Companies and Tools Related Companies ABOS Competitors CRBU Competitors ADAP Competitors LFCR Competitors CRBP Competitors IMMP Competitors MDWD Competitors VTYX Competitors CNTX Competitors LFVN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLNN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
